Veru Inc (VERU) received a Buy rating and a $4.50 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $1.35, close to its 52-week low of $1.17.
Selvaraju commented:
“Our price target is derived from a market value of the firm at $295M. This includes a discounted cash flow-based asset value of $305M for FC2 and Tamsulosin DRS, excluding $10M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -15.8% and a 24.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veru Inc with a $7.25 average price target, implying a 437.0% upside from current levels. In a report issued on January 15, Brookline Capital Markets also maintained a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.37 and a one-year low of $1.17. Currently, Veru Inc has an average volume of 78.2K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.
